Biopharmaceuticals: Obtained Clinical Trial Approval for Veterinary Biological Products.

Biological Co., Ltd. announced that its wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. recently received the clinical trial approval for the African swine fever vaccine from the Ministry of Agriculture and Rural Affairs. The vaccine is used for preventing African swine fever virus infection. The company will cooperate with research institutes in 2023 for research and development, with a total research and development investment of approximately 64 million yuan. The clinical trial will be conducted at Jinyu Baoling, and it will need to complete the clinical trial, submit for registration, and receive approval before it can be marketed.